

Anatara Lifesciences progressing towards first human clinical studies

Key highlights

- **Anatara anticipates launching Gastrointestinal Re-Programming (GaRP) trial recruitment website within the next two weeks**
- **Anatara anticipates commencing subject screening for enrolment in targeted delivery formulation (3FDC) Clinical Trial, assessing Psychological Functioning, in August**
- **Active program in place to progress commercialisation over the coming 6 to 12 months, including pursuing a potential partnership agreement**

MELBOURNE, 31 May 2021: Anatara Lifesciences (ASX: ANR), a developer of *evidence based* solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities.

Commenting on progress made towards the human clinical studies, CEO Steve Lydeamore said, “We are pleased to report on the progress made towards two separate human trials for our Gastrointestinal complementary medicines GaRP and 3FDC. Having recently completed the necessary pre-clinical safety and efficacy testing required to commence human trials and gained ethics approval, we are excited to be imminently commencing recruitment activities.

“We have completed the design of our trial recruitment website for the GaRP trial ahead of enrolments. We have also made progress towards our Psychological Functioning clinical trial with 3FDC, where the CSIRO team will develop work guidelines prior to initiating recruitment, which we anticipate occurring from August 2021.”

Irritable Bowel Syndrome (IBS) Trial Recruitment website to launch in June

Anatara has strong pre-clinical data to support GaRP use in IBS, the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care. In February, Anatara announced that it had received Human Research Ethics Committee approval to undertake a clinical trial of GaRP for participants with irritable bowel syndrome – diarrhoea subtype (IBS-D), having completed the required pre-clinical safety and efficacy testing.

The Company now anticipates launching the trial recruitment website and screening of subjects for enrolment in the trial within the next two weeks. Recruitment for phase one of this trial is anticipated to be completed in December 2021 following which a futility analysis will be undertaken to determine which dose of GaRP will progress in phase two of this trial.

Psychological Functioning Trial recruitment to commence in August

In April, Anantara advised that it had received Human Research Ethics Committee approval to undertake a clinical trial on the effects of 3FDC dietary supplementation on psychological functioning in an adult population, in collaboration with CSIRO.

3FDC is one of the components of Anantara's GaRP dietary supplement that exerts its effects due to absorption characteristics and influence on the microbiome in the large intestine. The gut-brain axis balance is considered important for depression, anxiety and stress symptoms in otherwise healthy individuals. The components of 3FDC and the delivery coating target the complex physiology of these considerations by ensuring the components are able to influence the important and relevant section of the GIT (gastrointestinal tract or 'gut').

The CSIRO team will develop the work guidelines and initiate recruitment with the aim of dosing the first participants in the third quarter of calendar year 2021. Anantara anticipates commencing screening of subjects in August 2021.

"More than ever, the world is looking for safe and effective solutions to gut health. The progress that Anantara has achieved in developing *evidence based* solutions for GIT is very encouraging. The human trials are the key next step to moving closer to commercialisation, and entering the US\$8+ billion gastrointestinal supplements and over-the-counter digestive remedies market¹."

"We have a very active program in place over the coming 6 to 12 months to progress the commercialisation of our health products, including pursuing a potential partnership agreement. We remain very encouraged about Anantara's future prospects", added Mr Lydeamore.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com	Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anantara.com

About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for human and animal health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

¹ Mintel's 2018 Digestive Health U.S. – July, 16; Nutrition Business Journal (NBJ)

Anantara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anantara.com | Website anataralifesciences.com

